Telix Pharmaceuticals (NASDAQ:TLX) Earns Buy Rating from HC Wainwright

Key Points

• HC Wainwright reaffirmed a Buy rating on Telix Pharmaceuticals with a $20 price target, implying approximately 56.9% upside from the stock’s recent $12.75 price.
• Telix shares rose 8.2% in Tuesday trading, reaching $12.75 near their 52-week high of $12.87. MarketBeat reports a consensus “Moderate Buy” rating and an average target price of $20.40.
• The FDA approved Telix’s Pixclara brain-cancer imaging agent for detecting and characterizing gliomas in adults and children, expanding the company’s radiopharmaceutical commercial opportunity.

Telix Pharmaceuticals (NASDAQ:TLX - Get Free Report)'s stock had its "buy" rating reissued by equities research analysts at HC Wainwright in a report issued on Tuesday, Benzinga reports. They currently have a $20.00 target price on the stock. HC Wainwright's target price would suggest a potential upside of 56.91% from the company's current price.

A number of other equities research analysts have also commented on TLX. Royal Bank Of Canada lowered Telix Pharmaceuticals from an "outperform" rating to a "sector perform" rating in a research report on Friday, July 17th. Weiss Ratings upgraded shares of Telix Pharmaceuticals from a "sell (d)" rating to a "hold (c-)" rating in a research note on Friday, August 21st. Citigroup reaffirmed a "buy" rating on shares of Telix Pharmaceuticals in a report on Thursday, August 20th. Finally, Wedbush reiterated an "outperform" rating and issued a $22.00 price objective on shares of Telix Pharmaceuticals in a research note on Monday. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and two have assigned a Hold rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $20.40.

Telix Pharmaceuticals Trading Up 8.2%

Shares of TLX stock traded up $0.97 during mid-day trading on Tuesday, reaching $12.75. The stock had a trading volume of 152,459 shares, compared to its average volume of 201,126. Telix Pharmaceuticals has a 1-year low of $6.28 and a 1-year high of $12.87. The company has a quick ratio of 1.85, a current ratio of 2.01 and a debt-to-equity ratio of 1.16. The business's fifty day moving average is $11.22 and its 200-day moving average is $10.20.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of TLX. Bank of America Corp DE grew its stake in shares of Telix Pharmaceuticals by 523.8% during the 1st quarter. Bank of America Corp DE now owns 10,031 shares of the company's stock worth $96,000 after purchasing an additional 8,423 shares during the period. XY Capital Ltd acquired a new stake in Telix Pharmaceuticals during the first quarter valued at $120,000. Lazard Asset Management LLC increased its holdings in Telix Pharmaceuticals by 15.7% in the first quarter. Lazard Asset Management LLC now owns 289,917 shares of the company's stock valued at $2,775,000 after buying an additional 39,400 shares in the last quarter. Private Advisor Group LLC increased its holdings in Telix Pharmaceuticals by 276.3% in the first quarter. Private Advisor Group LLC now owns 174,415 shares of the company's stock valued at $1,669,000 after buying an additional 128,070 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. acquired a new position in shares of Telix Pharmaceuticals in the second quarter worth about $1,731,000.

Telix Pharmaceuticals News Roundup

Here are the key news stories impacting Telix Pharmaceuticals this week:

• Positive Sentiment: The U.S. Food and Drug Administration approved Pixclara (floretyrosine F 18, or 18F-FET), Telix’s amino-acid PET imaging agent for detecting and characterizing gliomas, a form of brain cancer. The approval covers imaging in both adults and children, creating a significant commercial opportunity in the U.S. and advancing Telix’s radiopharmaceutical pipeline. FDA Approves Telix's Brain Cancer Imaging Drug Pixclara
• Positive Sentiment: Analysts at Wedbush reaffirmed an Outperform rating and set a $22 price target, signaling substantial potential upside from recent trading levels. The target provides additional investor confidence following the Pixclara approval. Wedbush rating coverage
• Neutral Sentiment: At the Morgan Stanley Global Healthcare Conference, Telix presented an overview of its business and development strategy. The event may improve visibility with institutional healthcare investors, although the supplied transcript does not identify a separate new financial forecast or material corporate announcement. Morgan Stanley Global Healthcare Conference Transcript

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals for the diagnosis and treatment of cancer and other serious diseases. Its products use targeted molecules to deliver radioactive isotopes to specific tissues, supporting precision imaging and therapeutic applications.

The company's commercial portfolio includes Illuccix, a gallium-68 radiolabeled prostate-specific membrane antigen (PSMA) imaging agent used with PET scans to help detect and manage prostate cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.